Am J Clin Pathol
- BRAR N, Lawrence L, Fung E, Zehnder JL, et al
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual
disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Am J Clin Pathol. 2024 Apr 20:aqae034. doi: 10.1093.
Am J Hematol
- YE Y, Labopin M, Gerard S, Yakoub-Agha I, et al
Lower relapse incidence with haploidentical versus matched sibling or unrelated
donor hematopoietic cell transplantation for core-binding factor AML patients in
CR2: A study from the Global Committee and the Acute Leukemia Working Party of
the Europea
Am J Hematol. 2024 Apr 24. doi: 10.1002/ajh.27342.
- ZHOU Z, Zhuo N, Zhou Y, Sun C, et al
Identification of the characteristics and prognostic impact of FUS::ERG and
RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients.
Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27340.
- SZUBER N, Orazi A, Tefferi A
Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update
on diagnosis, genetics, risk stratification, and management.
Am J Hematol. 2024 Apr 21. doi: 10.1002/ajh.27321.
Ann Hematol
- TAZOE K, Harada N, Makuuchi Y, Kuno M, et al
Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem
cell transplantation is a risk factor for death in patients with myelodysplastic
syndrome or chronic myelomonocytic leukemia.
Ann Hematol. 2024 Apr 25. doi: 10.1007/s00277-024-05772.
- BENCHIKH S, Charlene SSG, Bousfiha A, Razoki L, et al
Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco.
Ann Hematol. 2024 Apr 24. doi: 10.1007/s00277-024-05747.
Blood
- WIENECKE CP, Heida B, Venturini L, Gabdoulline R, et al
Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic
Hematopoietic Cell Transplantation.
Blood. 2024 Apr 26:blood.2023022697. doi: 10.1182/blood.2023022697.
- SUBKLEWE M
T cells take aim in AML: targeting IDH2.
Blood. 2024;143:1681-1682.
- TRAN TH, Tasian SK
How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in
Children, Adolescents, and Young Adults.
Blood. 2024 Apr 24:blood.2023023153. doi: 10.1182/blood.2023023153.
- ABDELBAKY SB, Giacopelli B, Rabe KG, Yamaguchi K, et al
Prediction of outcomes for high-count monoclonal B lymphocytosis using an
epigenetic and immunogenetic signature.
Blood. 2024;143:1752-1757.
BMC Cancer
- URGESSA F, Lengiso B, Tsegaye A, Gebremedhin A, et al
Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic
myeloid leukemia patients at presentation at a tertiary care teaching hospital in
Addis Ababa, Ethiopia: a cross-sectional study.
BMC Cancer. 2024;24:530.
- QIU Y, Bai L, Zhao H, Mei X, et al
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid
leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
BMC Cancer. 2024;24:520.
Eur J Haematol
- KUTSCH N, Godel P, Voltin CA, Hallek M, et al
Long-term remission in a patient with relapsed Richter's transformation treated
with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell
transplantation.
Eur J Haematol. 2024;112:984-987.
- GERHARDT A, Dorfel S, Schulz H, Schlag R, et al
Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results
from the German multicentre REALITY study.
Eur J Haematol. 2024;112:927-937.
- SKIPPER MT, Birkebaek N, Jensen RB, Rank CU, et al
Pancreas-related persisting sequelae in ALL survivors with a history of
asparaginase-associated pancreatitis: A part of the ALL-STAR study.
Eur J Haematol. 2024;112:944-956.
- MIKLOS E, Oliver TP, Adam K, Eva K, et al
Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia
patients.
Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14213.
- MARRA JD, Galli E, Giammarco S, Metafuni E, et al
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia
relapsing after hematopoietic stem cell transplantation.
Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14217.
- AFTANDILIAN C, Bito XR, Berman D, Zhang A, et al
Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy
in pediatric patients with relapsed/refractory leukemia.
Eur J Haematol. 2024 Apr 24. doi: 10.1111/ejh.14216.
Genes Chromosomes Cancer
- MAVRIDOU E, Lema Fernandez AG, Nardelli C, Pierini V, et al
A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in
myelodysplastic syndromes and acute myeloid leukemias.
Genes Chromosomes Cancer. 2024;63:e23235.
J Pediatr Hematol Oncol
- LI Y, Hu GH, Xu LP, Zhang XH, et al
CAR-T Therapy Followed by Hematopoietic Stem Cell Transplantation Can Improve
Survival in Children Relapsed/Refractory Philadelphia Chromosome-positive B-cell
Acute Lymphoblastic Leukemia.
J Pediatr Hematol Oncol. 2024 Apr 23. doi: 10.1097/MPH.0000000000002861.
Leuk Lymphoma
- NESR G, Claudiani S, Milojkovic D, Innes A, et al
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic
phase chronic myeloid leukemia.
Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758.
- STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al
Challenges in management of older patients with chronic myeloid leukemia.
Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559.
- BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients
with FLT3-mutant acute myeloid leukemia.
Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052.
- FLECK C, Karabinos A, Cook A, Moore DC, et al
Evaluation of safety outcomes with transitioning obinutuzumab from standard rate
to short duration infusion in patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
- ROGERS KA, Thompson PA
Pairing obinutuzumab with venetoclax in relapsed CLL.
Leuk Lymphoma. 2024;65:543-545.
- GARCIAZ S, Berton G, Hospital MA, Guille A, et al
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive
molecular data available.
Leuk Lymphoma. 2024;65:700-703.
- OKABE S, Moriyama M, Gotoh A
Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive
cells.
Leuk Lymphoma. 2024;65:696-699.
- FATIMA N, Shen Y, Crassini K, Burling O, et al
The CIpP activator, TR-57, is highly effective as a single agent and in
combination with venetoclax against CLL cells in vitro.
Leuk Lymphoma. 2024;65:585-597.
Leukemia
- GUO J, Buettner R, Du L, Li Z, et al
8-Cl-Ado and 8-NH(2)-Ado synergize with venetoclax to target the
methionine-MAT2A-SAM axis in acute myeloid leukemia.
Leukemia. 2024 Apr 20. doi: 10.1038/s41375-024-02222.
N Engl J Med
- BLAISE D
CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia.
N Engl J Med. 2024;390:1526-1527.
- HU Y, Zhang M, Yang T, Mo Z, et al
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
N Engl J Med. 2024;390:1467-1480.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016